Nanosomal Forms of Hepatoprotectors in Acute Liver Injury: A Review

Acute liver injury is accompanied by the development of oxidative stress, inflammatory reactions, and high mortality. The use of traditional hepatoprotectors is limited by their low bioavailability and nonspecific distribution. This review summarizes data from domestic and international sources (2005 – 2025) on the use of nanosomal forms (liposomes, niosomes, phytosomes, etc.) for the delivery of hepatoprotectors, including S-adenosylmethionine, N-acetylcysteine, ursodeoxycholic acid, silymarin, curcumin, L-ornithine-L-aspartate, and taurine. Nanosomal forms increase the stability and hepatic accumulation of active ingredients, reduce systemic toxicity, and enhance pharmacodynamics in preclinical models. Clinical data for most drugs are currently limited to individual early-phase studies. The results can be used for planning preclinical experiments and clinical trials of new nanoforms of hepatoprotectors for acute liver injury.